Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.

@article{Jabbour2011PredictiveFF,
  title={Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.},
  author={Elias J Jabbour and Hagop Kantarjian and Sallyann O'Brien and Jenny Shan and Guillermo Garcia-Manero and William G Wierda and Farhad Ravandi and Gautam Borthakur and Mary Beth Rios and Jorge E Cortes},
  journal={Blood},
  year={2011},
  volume={117 6},
  pages={1822-7}
}
We assessed the predictive factors for outcome and response in 123 patients with chronic myeloid leukemia in chronic phase treated with second-generation tyrosine kinase inhibitors (TKIs) after imatinib failure. Better event-free survival rates with second-generation TKI therapy were associated with a previous cytogenetic response to imatinib (P < .001) and a performance status of 0 (P = .001). Patients with 0, 1, or 2 adverse factors had 2-year event-free survival rates of 78%, 49%, and 20% (P… CONTINUE READING
38 Citations
27 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph chronic myelogenous leukemia (CML) [abstract

  • J Cortes, T Bruemmendorf, H Kantarjian
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…